Push to ease peptide restrictions positive for Hims & Hers, says Leerink

Leerink analyst Michael Cherny views Health and Human Services Secretary Robert Kennedy announcement that the FDA is seeking to remove 12 peptides from Category 2 restrictions as a “clear positive” for Hims & Hers. The lifting of restrictions would help “fill the growth hole” the company is likely to see from the transition to commercial weight loss products, the analyst tells investors in a research note. Leerink believes a positive recommendation from the advisory committee would allow Hims & Hers to leverage its existing peptide facility. “This would not immediately translate into revenue but would seemingly be a growth avenue that HIMS would push hard on,” the firm writes. It has a Market Perform rating on Hims & Hers. The stock in morning trading is up 5% to $25.60.